FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 288 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... January 21, 2021 Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome October 9, 2020 FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... May 9, 2022 Triple Therapy with Pertuzumab, Trastuzumab and Docetaxel is Feasible and Tolerable... February 3, 2022 Load more HOT NEWS Exercising Safely During Breast Cancer Treatment: What to Know ‘A significant step forwards’ – treating patients with advanced biliary tract... Mom Is Outraged After Finding Out Her Mother-In-Law Changed The Baby’s... FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic...
